Our Subsidaries

France Flag

Venipharm S.A.S.

Adress: 4 Bureaux de la Colline 92210 Saint-Cloud, France Tel.: (+33) 1 47 11 04 47 E-mail: venipharm@venipharm.com

Germany Flag

Venipharm GmbH

Adress: 21-23 Lademannbogen, 22339 Hamburg, Germany Tel.: (+49) 40822161501 E-mail: Info-deutschland@venipharm.com www.enoxaparin-ledraxen.de

England Flag

Venipharm Ltd

Adress: 8th Floor South, 11 Old Jewry, London, EC2R 8DU United Kingdom Tel.: (+44) 07425 909367 E-mail: gurmakh.roopra@venipharm.com

Data Confidentiality

We collect your personal data for the sole purpose of managing recruitment, contracts and pharmacovigilance (health monitoring and medical information). By providing your data on this site, you consent to their collection, use and storage by Venipharm for the purposes set out above. For more information on how we handle your personal information and to exercise your rights, please see our Venipharm Privacy Policy.

Contact Venipharm Pharmacovigilance

At Venipharm, we take the safety of our patients very seriously and continuously monitor the safety of our products. If you have any adverse reactions to Venipharm products, please report them to us by sending an e-mail to pharmacovigilance@venipharm.com or by calling 01 47 11 04 47 (choice #2). We remind you that healthcare professionals must report any suspected adverse reaction to the Centre Régional de Pharmacovigilance (CRPV) (Regional Pharmacovigilance Centre) on which they depend and any case of abuse or drug dependence must be reported to the Centre d'Évaluation et d'Information sur la Pharmacodépendance (CEIP-A) (Drug Dependence Assessment and Information Centre) on which they depend (https://signalement.social-sante.gouv.fr). The personal data collected by Venipharm as part of the management of pharmacovigilance cases is described in the guidelines issued by the Commission Nationale Informatique et Liberté (‘CNIL’) relating to the processing of personal data implemented for the purposes of health vigilance management. They are used and shared solely for pharmacovigilance purposes.